Last reviewed · How we verify
VBMCP/VBAD/Velcade
Velcade works by inhibiting the proteasome, a complex within cells that breaks down proteins.
Velcade works by inhibiting the proteasome, a complex within cells that breaks down proteins. Used for Multiple myeloma, Mantle cell lymphoma.
At a glance
| Generic name | VBMCP/VBAD/Velcade |
|---|---|
| Sponsor | PETHEMA Foundation |
| Drug class | Proteasome inhibitor |
| Target | 20S proteasome |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the proteasome, Velcade disrupts the normal functioning of cells, leading to cell death, particularly in cancer cells. This mechanism is particularly effective in multiple myeloma and mantle cell lymphoma.
Approved indications
- Multiple myeloma
- Mantle cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |